FDC Limited (FDC)
Press Release Q1 FY 2026-27 Results.
Press Release - Q1FY27
- Revenue 668cr +3.0% y-y; EBITDA 143cr +1.9% y-y; EBITDA margin 21.4% (21.6%) -20 bps y-y; PAT 132cr +9.2% y-y
- International Formulations grew 74.2% y-y, driven by US business (+118.4%) and Non-US (+47.7%) in Q1 FY27
- Domestic Formulations declined 1.9% y-y, impacted by select key brands; accounted for 85% of sales
- API sales declined 2.9% y-y, contributing 4% of consolidated sales
- Received US FDA approval for Cefixime Oral Suspension 100mg/5mL and 200mg/5mL during the quarter
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 FDC — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add FDC to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on FDC Limited
Important.
The summary above is generated automatically from FDC Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.